SMT202000591T1 - Ligandi pet radiomarcati mglur 2/3 - Google Patents
Ligandi pet radiomarcati mglur 2/3Info
- Publication number
- SMT202000591T1 SMT202000591T1 SM20200591T SMT202000591T SMT202000591T1 SM T202000591 T1 SMT202000591 T1 SM T202000591T1 SM 20200591 T SM20200591 T SM 20200591T SM T202000591 T SMT202000591 T SM T202000591T SM T202000591 T1 SMT202000591 T1 SM T202000591T1
- Authority
- SM
- San Marino
- Prior art keywords
- pet ligands
- mglur2
- radiolabelled
- radiolabelled mglur2
- ligands
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15201240 | 2015-12-18 | ||
| PCT/EP2016/081542 WO2017103182A1 (en) | 2015-12-18 | 2016-12-16 | Radiolabelled mglur2/3 pet ligands |
| EP16812961.7A EP3389727B1 (en) | 2015-12-18 | 2016-12-16 | Radiolabelled mglur2/3 pet ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202000591T1 true SMT202000591T1 (it) | 2020-11-10 |
Family
ID=55023944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20200591T SMT202000591T1 (it) | 2015-12-18 | 2016-12-16 | Ligandi pet radiomarcati mglur 2/3 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11033641B2 (it) |
| EP (1) | EP3389727B1 (it) |
| JP (1) | JP6927974B2 (it) |
| AU (1) | AU2016374571B2 (it) |
| CA (1) | CA3003998A1 (it) |
| CY (1) | CY1124935T1 (it) |
| DK (1) | DK3389727T3 (it) |
| ES (1) | ES2828976T3 (it) |
| HR (1) | HRP20201372T1 (it) |
| HU (1) | HUE050665T2 (it) |
| LT (1) | LT3389727T (it) |
| PL (1) | PL3389727T3 (it) |
| PT (1) | PT3389727T (it) |
| RS (1) | RS60981B1 (it) |
| SI (1) | SI3389727T1 (it) |
| SM (1) | SMT202000591T1 (it) |
| WO (1) | WO2017103182A1 (it) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| RU2711382C2 (ru) | 2014-12-03 | 2020-01-16 | Янссен Фармацевтика Нв | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 |
| EP3226915B1 (en) | 2014-12-03 | 2019-02-20 | Janssen Pharmaceutica NV | Radiolabelled mglur2 pet ligands |
| JP6929285B2 (ja) * | 2015-12-18 | 2021-09-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド |
| RS60981B1 (sr) | 2015-12-18 | 2020-11-30 | Janssen Pharmaceutica Nv | Radiooznačeni mglur2/3 pet ligandi |
| WO2019103070A1 (ja) | 2017-11-24 | 2019-05-31 | 大日本住友製薬株式会社 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0756200B1 (en) | 1995-07-26 | 1999-11-10 | Konica Corporation | Silver halide color photographic light-sensitive material |
| DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
| US6831074B2 (en) | 2001-03-16 | 2004-12-14 | Pfizer Inc | Pharmaceutically active compounds |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| US7329662B2 (en) | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| WO2005061507A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof |
| BRPI0512330A (pt) | 2004-06-21 | 2008-02-26 | Hoffmann La Roche | derivados de pirazol-pirimidina |
| WO2006030847A1 (ja) | 2004-09-17 | 2006-03-23 | Dainippon Sumitomo Pharma Co., Ltd. | 新規二環性ピラゾール誘導体 |
| DE102004054665A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| BRPI0607927A2 (pt) | 2005-02-11 | 2009-10-20 | Hoffmann La Roche | derivados de pirazol-pirimidina |
| WO2006099972A1 (en) | 2005-03-23 | 2006-09-28 | F. Hoffmann-La Roche Ag | Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists |
| WO2007084314A2 (en) | 2006-01-12 | 2007-07-26 | Incyte Corporation | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
| JP5523829B2 (ja) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| ES2395583T3 (es) | 2007-05-10 | 2013-02-13 | Ge Healthcare Limited | IMIDAZOL (1,2-A)PIRIDINAS y compuestos relacionados con actividad frente a los receptores cannabinoides CB2 |
| EP2085390A1 (en) | 2008-01-31 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
| US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
| AU2009228765B2 (en) | 2008-03-24 | 2012-05-31 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| WO2009130232A1 (en) | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
| US20110230472A1 (en) | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
| EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP2013537210A (ja) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| US20130230459A1 (en) * | 2010-11-08 | 2013-09-05 | Janssen Pharmaceuticals, Inc. | RADIOLABELLED mGluR2 PET LIGANDS |
| JP2013545822A (ja) | 2010-12-17 | 2013-12-26 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ５受容体のアロステリック調節剤としての、二環式トリアゾールラクタムおよびピラゾールラクタム |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
| HK1198443A1 (en) | 2011-07-19 | 2015-04-24 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| IN2014CN03234A (it) | 2011-11-03 | 2015-07-03 | Merck Sharp & Dohme | |
| JP2013189395A (ja) | 2012-03-14 | 2013-09-26 | Dainippon Sumitomo Pharma Co Ltd | ジヒドロピロロピラジノン誘導体 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| EP2666775A1 (en) | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| US20130345204A1 (en) | 2012-06-20 | 2013-12-26 | Vanderbilt University | Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| US20130345205A1 (en) | 2012-06-20 | 2013-12-26 | Vanderbilt University | Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| WO2013192343A1 (en) | 2012-06-20 | 2013-12-27 | Vanderbilt University | Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors |
| BR112015000106B1 (pt) | 2012-07-03 | 2022-02-22 | Sagimet Biosciences Inc | Moduladores heterocíclicos de síntese de lipídio, composição farmacêutica e uso dos referidos moduladores |
| CN104736140A (zh) | 2012-10-23 | 2015-06-24 | 霍夫曼-拉罗奇有限公司 | 用于治疗自闭症的mGlu2/3拮抗剂 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| DK3013813T3 (da) | 2013-06-27 | 2019-06-03 | Pfizer | Heteroaromatiske forbindelser og anvendelse deraf som dopamin-d1-ligander |
| PT3030563T (pt) | 2013-06-27 | 2017-11-15 | Janssen Sciences Ireland Uc | Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças |
| AU2015295301B2 (en) | 2014-08-01 | 2019-05-09 | Janssen Pharmaceutica Nv | 6,7-dihydropyrazolo[1,5-alpha]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JO3601B1 (ar) * | 2014-08-01 | 2020-07-05 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| CA2954091C (en) | 2014-08-01 | 2022-08-02 | Janssen Pharmaceutica Nv | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors |
| EP3226915B1 (en) | 2014-12-03 | 2019-02-20 | Janssen Pharmaceutica NV | Radiolabelled mglur2 pet ligands |
| RU2711382C2 (ru) | 2014-12-03 | 2020-01-16 | Янссен Фармацевтика Нв | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 |
| JP2016124810A (ja) | 2014-12-26 | 2016-07-11 | 大日本住友製薬株式会社 | 新規縮合ピラゾール誘導体およびその医薬用途 |
| JP6929285B2 (ja) * | 2015-12-18 | 2021-09-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド |
| RS60981B1 (sr) | 2015-12-18 | 2020-11-30 | Janssen Pharmaceutica Nv | Radiooznačeni mglur2/3 pet ligandi |
-
2016
- 2016-12-16 RS RS20201288A patent/RS60981B1/sr unknown
- 2016-12-16 PL PL16812961T patent/PL3389727T3/pl unknown
- 2016-12-16 HR HRP20201372TT patent/HRP20201372T1/hr unknown
- 2016-12-16 PT PT168129617T patent/PT3389727T/pt unknown
- 2016-12-16 JP JP2018531628A patent/JP6927974B2/ja not_active Expired - Fee Related
- 2016-12-16 LT LTEP16812961.7T patent/LT3389727T/lt unknown
- 2016-12-16 HU HUE16812961A patent/HUE050665T2/hu unknown
- 2016-12-16 CA CA3003998A patent/CA3003998A1/en active Pending
- 2016-12-16 SM SM20200591T patent/SMT202000591T1/it unknown
- 2016-12-16 DK DK16812961.7T patent/DK3389727T3/da active
- 2016-12-16 US US16/061,437 patent/US11033641B2/en not_active Expired - Fee Related
- 2016-12-16 ES ES16812961T patent/ES2828976T3/es active Active
- 2016-12-16 EP EP16812961.7A patent/EP3389727B1/en active Active
- 2016-12-16 SI SI201630916T patent/SI3389727T1/sl unknown
- 2016-12-16 AU AU2016374571A patent/AU2016374571B2/en not_active Ceased
- 2016-12-16 WO PCT/EP2016/081542 patent/WO2017103182A1/en not_active Ceased
-
2020
- 2020-11-09 CY CY20201101051T patent/CY1124935T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6927974B2 (ja) | 2021-09-01 |
| SI3389727T1 (sl) | 2020-10-30 |
| LT3389727T (lt) | 2020-10-12 |
| AU2016374571B2 (en) | 2021-05-06 |
| WO2017103182A1 (en) | 2017-06-22 |
| AU2016374571A1 (en) | 2018-05-17 |
| HRP20201372T1 (hr) | 2020-11-27 |
| PL3389727T3 (pl) | 2021-02-08 |
| EP3389727B1 (en) | 2020-08-12 |
| EP3389727A1 (en) | 2018-10-24 |
| CY1124935T1 (el) | 2022-07-22 |
| CA3003998A1 (en) | 2017-06-22 |
| US11033641B2 (en) | 2021-06-15 |
| HUE050665T2 (hu) | 2020-12-28 |
| DK3389727T3 (da) | 2020-11-02 |
| US20200306389A1 (en) | 2020-10-01 |
| ES2828976T3 (es) | 2021-05-28 |
| JP2019502700A (ja) | 2019-01-31 |
| RS60981B1 (sr) | 2020-11-30 |
| PT3389727T (pt) | 2020-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201507594D0 (en) | Intamac 1 | |
| GB201521134D0 (en) | Privitar case 1 | |
| IL259966B (en) | Radiolabelled mglur2/3 pet ligands | |
| SI3389727T1 (sl) | Radioaktivno označeni ligandi PET MGLUR2/3 | |
| GB201513478D0 (en) | Pet hideaways | |
| AU5457P (en) | JOAe 6656 Aeonium arborium | |
| GB201521156D0 (en) | Concept 80 | |
| GB201521158D0 (en) | Concept 82 | |
| GB201521157D0 (en) | Concept 74 | |
| GB201521164D0 (en) | Concept 85 | |
| GB201521163D0 (en) | Concept 78 | |
| GB201505171D0 (en) | Concept 37 | |
| GB201505176D0 (en) | Concept 43 | |
| GB201505151D0 (en) | Concept 30 | |
| GB201505164D0 (en) | Concept 16 | |
| GB201505169D0 (en) | Concept 36 | |
| GB201505172D0 (en) | Concept 38 | |
| GB201505173D0 (en) | Concept 39 | |
| GB201505174D0 (en) | Concept 40 | |
| GB201505154D0 (en) | Concept 22 | |
| GB201505179D0 (en) | Concept 54 | |
| GB201505180D0 (en) | Concept 53 | |
| GB201505183D0 (en) | Concept 52 | |
| GB201505153D0 (en) | Concept 23 | |
| GB201505152D0 (en) | Concept 29 |